HRB CRCI seeks Clinical Trial Monitor/Liaison Officer

Post Title: Clinical Trial Monitor/Liaison Officer, HRB Clinical Research Coordination Ireland
Post Status: Contract of Indefinite Duration
Organisation: MMI Clinical Research Development Ireland CLG (CRDI)
Location: 28 Mount St Upper, Dublin 2
Reports to: Chief Operations Officer HRB CRCI and HRB CRCI Chair with a dotted report line to the Lead Clinical Trial Liaison Office for the Feasibility and Study Development Programme
Salary: Commensurate with experience
Closing Date: Friday 19 January 2018
Application Process: Curriculum Vitae and covering letter containing names of 3 referees to be sent to info@crdi.ie

With the support of the Health Research Board, Enterprise Ireland and Molecular Medicine Ireland, the five University-based Clinical Research Facilities/Centres (CRF/Cs) in the Republic of Ireland have developed an integrated clinical trials network, the Health Research Board Clinical Research Co-ordination Ireland (HRB CRCI).

The aim of the HRB CRCI is to enhance Ireland’s capacity for conducting innovative high quality clinical research for the benefit of people’s health and the economy. It will advance the care of patients by enabling a connected and coordinated Clinical Trial Network. This network provides the skills, expertise and infrastructure to design, conduct and analyse multi-centre clinical trials involving human participants in Ireland. It supports both academic or industry initiated clinical trials involving pharmaceuticals, nutriceuticals or clinical care pathways as well as clinical investigation of medical devices.

The HRB CRCI now wishes to appoint a Clinical Trial Monitor/Liaison Officer.

The position is for a high-calibre experienced candidate to deliver the HRB CRCI Clinical Trial support services as per the HRB CRCI’s 5 year business plan, working in close collaboration with the HRB CRCI Chief Operations Officer, the HRB CRCI Chair and the HRB CRCI team both in the central office and at a local level.

The full job description can be viewed here.